Total Payments
$156,359
2024 Payments
$156.45
Companies
25
Transactions
97
Medicare Patients
63
Medicare Billing
$16,714
Payment Breakdown by Category
Consulting$137,475 (87.9%)
Other$12,748 (8.2%)
Travel$4,345 (2.8%)
Food & Beverage$1,521 (1.0%)
Education$162.13 (0.1%)
Research$107.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $137,475 | 44 | 87.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,748 | 9 | 8.2% |
| Travel and Lodging | $4,345 | 17 | 2.8% |
| Food and Beverage | $1,521 | 21 | 1.0% |
| Education | $162.13 | 4 | 0.1% |
| Unspecified | $107.80 | 2 | 0.1% |
Payments by Type
General
$156,251
95 transactions
Research
$107.80
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32,768 | 10 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $15,595 | 24 | $0 (2021) |
| GENZYME CORPORATION | $14,873 | 5 | $0 (2022) |
| F. Hoffmann-La Roche AG | $11,248 | 8 | $0 (2019) |
| PFIZER INC. | $9,827 | 5 | $0 (2019) |
| Daiichi Sankyo Inc. | $9,783 | 5 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $8,563 | 3 | $0 (2022) |
| Amgen Inc. | $8,550 | 1 | $0 (2017) |
| Alkermes, Inc. | $8,300 | 5 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $6,264 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156.45 | 4 | E.R. Squibb & Sons, L.L.C. ($134.53) |
| 2023 | $178.16 | 2 | Seagen Inc. ($151.73) |
| 2022 | $8,007 | 4 | GENZYME CORPORATION ($2,884) |
| 2021 | $35,148 | 18 | GENZYME CORPORATION ($9,156) |
| 2020 | $42,446 | 8 | Novartis Pharmaceuticals Corporation ($28,950) |
| 2019 | $28,109 | 25 | PFIZER INC. ($8,327) |
| 2018 | $12,723 | 18 | Merck Sharp & Dohme Corporation ($5,110) |
| 2017 | $29,592 | 18 | Amgen Inc. ($8,550) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $2.94 | General |
| 08/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $5.49 | General |
| 08/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $126.10 | General |
| Category: Oncology | ||||||
| 02/15/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Rare Disease | ||||||
| 06/05/2023 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $151.73 | General |
| 06/05/2023 | Blueprint Medicines Corporation | — | Food and Beverage | In-kind items and services | $26.43 | General |
| 10/13/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 07/21/2022 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,884.00 | General |
| Category: Oncology | ||||||
| 06/16/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 01/12/2022 | EMD Serono, Inc. | TEPMETKO (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Oncology | ||||||
| 12/06/2021 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/03/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| Category: Oncology | ||||||
| 11/03/2021 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,616.00 | General |
| 10/26/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,226.25 | General |
| 08/12/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2021 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,270.00 | General |
| Category: Oncology | ||||||
| 07/13/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2021 | Ipsen Biopharmaceuticals, Inc | ONIVYDE (Drug) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: Oncology | ||||||
| 06/28/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| 06/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2021 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,270.00 | General |
| Category: Oncology | ||||||
| 04/25/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 03/25/2021 | Daiichi Sankyo Inc. | Enhertu (Drug) | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2021 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $543.65 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $40.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase 1, multicenter, open-label, dose-escalation study of SGN 2FF in patients with advanced solid tumors | Seattle Genetics, Inc. | $107.80 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 26 | 60 | $17,469 | $7,363 |
| 2021 | 2 | 26 | 57 | $16,870 | $7,707 |
| 2020 | 1 | 11 | 11 | $3,895 | $1,644 |
Total Patients
63
Total Services
128
Medicare Billing
$16,714
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 45 | $14,103 | $5,905 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 15 | $3,366 | $1,457 | 43.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 46 | $14,384 | $6,542 | 45.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 11 | $2,486 | $1,166 | 46.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $3,895 | $1,644 | 42.2% |
About Dr. Laura Chow, MD
Dr. Laura Chow, MD is a Medical Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2009. The National Provider Identifier (NPI) number assigned to this provider is 1063745727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laura Chow, MD has received a total of $156,359 in payments from pharmaceutical and medical device companies, with $156.45 received in 2024. These payments were reported across 97 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($137,475).
As a Medicare-enrolled provider, Chow has provided services to 63 Medicare beneficiaries, totaling 128 services with total Medicare billing of $16,714. Data is available for 3 years (2020–2022), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Seattle, WA
- Active Since 09/14/2009
- Last Updated 09/18/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1063745727
Products in Payments
- ZYKADIA (Drug) $30,415
- TECENTRIQ (Biological) $16,724
- LIBTAYO (Biological) $13,243
- IMLYGIC (Biological) $8,550
- Enhertu (Drug) $6,931
- TAGRISSO (Drug) $6,508
- ALUNBRIG (Drug) $6,264
- ONIVYDE (Drug) $6,200
- Heplisav-B (Drug) $5,538
- NO PRODUCT DISCUSSED (Drug) $2,833
- KEYTRUDA (Biological) $2,676
- TEPMETKO (Drug) $2,100
- IMFINZI (Biological) $2,055
- ZEPZELCA (Drug) $1,920
- TABRECTA (Drug) $1,875
- OPDIVO (Biological) $126.10
- CYRAMZA (Drug) $100.39
- Alecensa (Biological) $37.09
- ULTOMIRIS (Biological) $21.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Seattle
Bart Scott
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Petros Grivas, M.d, M.D
Medical Oncology — Payments: $683,103
Medical Oncology $683,103
Evan Yu
Medical Oncology — Payments: $356,321
Medical Oncology $356,321
Gary Lyman, Md, MD
Medical Oncology — Payments: $176,021
Medical Oncology $176,021
Jerald Radich, Md, MD
Medical Oncology — Payments: $171,817
Medical Oncology $171,817
David Maloney
Medical Oncology — Payments: $167,323
Medical Oncology $167,323